Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (SCIg) (Hizentra®) cannot be endorsed for use within NHS Wales for the treatment of patients with chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with IVIg. |
||
|
||
Medicine details |
||
| Medicine name | human normal immunoglobulin (SCIg) (Hizentra®) | |
| Formulation | 200 mg/ml solution for injection | |
| Reference number | 3711 | |
| Indication | Treatment of patients with chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with IVIg. |
|
| Company | CSL Behring UK Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/07/2018 | |